Acute Myeloid Leukemia Clinical Trial

Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

Summary

This research study is designed to selectively deplete CD117-positive cells from participants with AML and MDS-EB.

View Full Description

Full Description

This is a multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential anti-leukemia activity and to establish the minimum safe and biologically-effective dose of a single dose of MGTA-117 in relapsed/refractory (R/R) CD117+ AML participants and participants with MDS-EB. The study consists of escalating single-dose cohorts using a standard 3+3 design.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant must have a World Health Organization (WHO)-defined diagnosis of R/R AML and meet one of the following criteria:

- The participant has experienced primary AML induction failure or R/R AML

OR

- The participant has a WHO-defined diagnosis of MDS-EB and has failed/is refractory to HMA

OR

- Presence of MRD in morphologic CR

CD117+ based on IHC or flow cytometry
Participant must have an identified HSC donor (related donor or unrelated donor), haplo-identical transplant donor, or umbilical blood donor.
Participant's Eastern Cooperative Oncology Group (ECOG) performance status must be ≤2.
Participant must have adequate baseline hepatic function. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤2 x upper limit of normal (ULN), and serum bilirubin ≤1.5 x ULN.
Estimated creatinine clearance ≥60 mL/min
Adequate cardiac function as demonstrated by cardiac left ventricular ejection fraction ≥40% or perform New York Heart Association (NYHA) classification I and II

Exclusion Criteria:

Acute promyelocytic leukemia (APL).
Known active central nervous system (CNS) leukemia or chloroma (granulocyte sarcoma).
Received HSCT within 6 months prior to dosing
Received chimeric antigen-receptor cell therapies within 6 months prior to dosing
Has active graft-versus-host disease (GVHD).
Active hepatitis B (Hep-B) or hepatitis C (Hep-C) infection or history of human immunodeficiency virus (HIV).
Participant with a QTc value >470 msec
Participant has received another investigational drug or device within 14 days or 5 half-lives of dosing, whichever is longer.
Participant has any clinically significant medical condition, which in the opinion of the Investigator may place the participant at an unacceptable risk.
Active uncontrolled systemic bacterial, fungal, or viral infection
Participant has a history of serious allergic reactions, which in the opinion of the Investigator may pose an increased risk of serious infusion reactions.
Participant has had any systemic antileukemia treatment within 14 days except hydroxyurea, which is permitted until 24 hours prior to MGTA-117 dosing.
Participant has received prior anti-CD117 antibody treatment.
Participant has received gemtuzumab ozogamicin (Mylotarg) within the last 3 months prior to dosing.
Participant has received recent monoclonal antibody as anti-leukemic therapy within the last 30 days or 5 half-lives, whichever is longer.
Participant has received recent vaccination within the last 14 days prior to dosing.
Participant has Grade 2 or higher electrolyte abnormality at screening

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

55

Study ID:

NCT05223699

Recruitment Status:

Recruiting

Sponsor:

Magenta Therapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 8 Locations for this study

See Locations Near You

City of Hope
Duarte California, 91010, United States
Sarah Cannon Research Institute at HealthONE
Denver Colorado, 80218, United States
Moffitt Cancer Center
Tampa Florida, 33612, United States
The University of Kansas Cancer Center
Westwood Kansas, 66205, United States
University of Minnesota
Minneapolis Minnesota, 55455, United States
Washington University School of Medicine
Saint Louis Missouri, 63110, United States
Roswell Park Comprehensive Cancer Center
Buffalo New York, 14203, United States
MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

55

Study ID:

NCT05223699

Recruitment Status:

Recruiting

Sponsor:


Magenta Therapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.